Publication Month: Feb 2022 | Report Code: TIPRE00008648 | No. of Pages: 174 | Category: Medical Device | Status: Published
Biopharmaceutical tubing are specifically designed to meet critical needs of biopharmaceutical and medical industries. This tubing is produced by the extrusion process and is extensively used in drug delivery systems, feeding tubes, and peristaltic pumps as well in a wide range of minimally critical invasive applications, including stent delivery systems, cardiovascular catheters, and urological retrieval devices. Moreover, these are also used with anesthesiology and respiratory equipment, IVs, and biopharmaceutical laboratory equipment. They confer exceptional thermal, mechanical, and chemical properties.
|Market Size Value in||US$ 3,442.82 Million in 2021|
|Market Size Value by||US$ 6,013.27 Million by 2028|
|Growth rate||CAGR of 8.3% from 2021-2028|
|No. of Pages||174|
|No. of Tables||86|
|No. of Charts & Figures||70|
|Historical data available||Yes|
|Segments covered||Type and Application|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The biopharmaceutical tubing market is segmented on the bases of type, application, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report offers insights and in-depth analysis of the market, emphasizing on parameters such as market trends, technological advancements, and market dynamics along with the analysis of competitive landscape of world’s leading market players.
Increase in life expectancy is leading to rise in geriatric population in the world. According to the World Health Organization (WHO), the global population share of people with age more than 60 would nearly double from 12% in 2015 to 22% in 2050. According to the United Nation’s World Population Ageing 2017 report, in 2017, there were 962 million people with age 60 or above in the world, and the number is expected to reach ~2.1 billion by 2050. In addition, according to the US Census Bureau, the number of people in the US with age 65 and above is anticipated to grow from 46 million in 2016 to more than 98 million by 2060, their population share would grow from ~15% to ~24% during this period. According to the United Nation’s World Population Ageing 2017 report, in 2017, Europe had the highest percentage of people of age more than 60, i.e., 25%. By 2050, ~25% or more population in all regions of the world, except Africa, would be of age 60 and above. The geriatric population in the world is anticipated to reach US$ 1.4 billion, US$ 2.1 billion, and above US$ 3.1 billion by 2030, 2050, and 2100, respectively.
This rise in the elderly population has led to an increase in the geriatric ailments, thus generating a greater demand for diagnostic equipment and drug delivery systems. It is also resulting in the spike in incidence of urological conditions that require catheterization. Medical professionals are also encouraging self-catheterization to reduce the cost and period of hospitalization as well as to avert the risk of healthcare-associated infections (HAI). Aging is also a main factor that contributes to the surge in the incidence of chronic diseases that might lead to the need for interventions that require admission to ICUs. Thus, rapid growth in the geriatric population is directly proportional to the rising demand for medical devices that incorporate tubing, drug delivery, dialysis and cardiac bypass, peristaltic pump, and sterile filling and dispensing systems, thereby driving the adoption of biopharmaceutical tubing systems.
A minimally invasive medical procedure is generally carried out by inserting a small device or an implant in body through an incision or anatomical opening. The popularity of these procedures has increased in the recent years due to the involvement of tiny incisions, faster recovery of patients, and less discomfort caused to the patients. Moreover, these procedures are also associated with benefits such as less trauma to muscles, nerves, tissues, and organs; less bleeding and scarring; and minimal injuries to tissues and less pain.
The growing prevalence of arthritis, cancer, and cardiovascular diseases, all of which require extensive surgical treatments, has boosted demand for minimally invasive procedures. As a result, there is an enormous demand for catheters and biopharmaceutical tubing, among other components. Furthermore, biopharmaceutical tubing systems are reasonably priced and aid in time-saving procedures. For example, employing catheter tubing for cardiac and urine catheterization significantly lowers the time required for the medical or surgical operation. Therefore, the growing demand for minimally invasive medical procedures and focus on increasing the efficiency of these procedures play an important role in propelling the demand for biopharmaceutical tubing.
Based on type, the global biopharmaceutical tubing market is segmented into plastic, metal, and silicone. In 2020, the silicone segment held the largest share of the market. Moreover, the market for the silicone segment is expected to grow at the highest CAGR during 2021–2028. The biocompatibility of silicone allows it to be compatible with human tissues and body fluids, increasing its use in medical tubing. In addition to biocompatibility, high temperature and chemical resistance, mechanical strength, and electric properties are among the properties that make it a material of choice in biological applications.
Based on application, the biopharmaceutical tubing market is segmented into pharmaceutical, medical devices, research and development, and others. The pharmaceutical segment is sub segmented as single use technology and others. The pharmaceutical segment held the largest market share in 2020, and it is further expected to be the largest shareholder in the market by 2028. Liquid transfer is an essential part of pharmaceutical manufacturing processes, including the manufacturing of cough syrup and complex active pharmaceutical ingredients (APIs) such as vaccines or specific medications for cancer treatment, and the transfer process must be carried out in a highly regulated environment. Thus, with the growing emphasis on proper transfer tubing systems with escalating production capacities, the pharmaceutical industries demand ultra-pure and corrosion-resistant systems for liquid transfer that withstand harsh environment of chemicals, which is bolstering the market growth of this segment.
Product launches, and mergers and acquisitions are the highly adopted strategies by the players operating in the global biopharmaceutical tubing market. A few of the recent key product developments are listed below:
In September 2021, DuPont introduced DuPont Liveo, a new brand name for its extensive range of silicone healthcare solutions. The Liveo brand product line includes pharmaceutical tubing and overmolded assemblies for single-use systems in biopharma processing, transdermal and topical drug delivery systems, and medical adhesives, among others.
In June 2020, Nordson acquired Fluortek, a plastic extrusion manufacturer that provides custom dimensioned tubing to the medical device industry. As Nordson Medical continues to expand its diversified product offerings, the acquisition enhances company's ability to deliver critical components for medical device innovations.
The COVID-19 pandemic is having the mixed impact on the biopharmaceutical tubing market. Growing COVID-19 infection in people with existing medical conditions such as asthma and diabetes also influences the growth of the market. There is a rise in the demand for drug delivery devices and equipment such as nasogastric tubes, nebulizers, spacer devices, etc. Therefore, these factors are driving the demand for biopharmaceutical tubing during the forecast period. On the other hand, many countries have changed medical device regulations owing to supply chain obstruction affect negatively on biopharmaceutical tubing market.